Cognition Therapeutics Statistics
Total Valuation
CGTX has a market cap or net worth of $98.90 million. The enterprise value is $65.47 million.
| Market Cap | 98.90M |
| Enterprise Value | 65.47M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CGTX has 95.09 million shares outstanding. The number of shares has increased by 65.45% in one year.
| Current Share Class | 95.09M |
| Shares Outstanding | 95.09M |
| Shares Change (YoY) | +65.45% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 1.76% |
| Owned by Institutions (%) | 17.50% |
| Float | 87.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.99 |
| P/TBV Ratio | 2.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.03, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.03 |
| Quick Ratio | 6.78 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,815.46 |
Financial Efficiency
Return on equity (ROE) is -83.76% and return on invested capital (ROIC) is -111.29%.
| Return on Equity (ROE) | -83.76% |
| Return on Assets (ROA) | -78.18% |
| Return on Invested Capital (ROIC) | -111.29% |
| Return on Capital Employed (ROCE) | -109.43% |
| Weighted Average Cost of Capital (WACC) | 14.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.25% in the last 52 weeks. The beta is 1.79, so CGTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -29.25% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 53.02 |
| Average Volume (20 Days) | 365,353 |
Short Selling Information
The latest short interest is 7.86 million, so 8.27% of the outstanding shares have been sold short.
| Short Interest | 7.86M |
| Short Previous Month | 7.13M |
| Short % of Shares Out | 8.27% |
| Short % of Float | 8.99% |
| Short Ratio (days to cover) | 14.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.60M |
| Pretax Income | -16.78M |
| Net Income | -16.78M |
| EBITDA | -36.55M |
| EBIT | -36.60M |
| Earnings Per Share (EPS) | -$0.19 |
Balance Sheet
The company has $34.01 million in cash and $589,000 in debt, with a net cash position of $33.42 million or $0.35 per share.
| Cash & Cash Equivalents | 34.01M |
| Total Debt | 589,000 |
| Net Cash | 33.42M |
| Net Cash Per Share | $0.35 |
| Equity (Book Value) | 33.02M |
| Book Value Per Share | 0.35 |
| Working Capital | 32.85M |
Cash Flow
In the last 12 months, operating cash flow was -$17.68 million and capital expenditures -$20,000, giving a free cash flow of -$17.70 million.
| Operating Cash Flow | -17.68M |
| Capital Expenditures | -20,000 |
| Depreciation & Amortization | 50,000 |
| Net Borrowing | -344,000 |
| Free Cash Flow | -17.70M |
| FCF Per Share | -$0.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -65.45% |
| Shareholder Yield | -65.45% |
| Earnings Yield | -16.96% |
| FCF Yield | -17.90% |
Analyst Forecast
The average price target for CGTX is $3.33, which is 220.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.33 |
| Price Target Difference | 220.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |